TY - JOUR
T1 - Serum phosphatidylserine-specific phospholipase A1 as a novel biomarker for monitoring systemic lupus erythematosus disease activity
AU - Sawada, Tetsuji
AU - Kurano, Makoto
AU - Shirai, Harumi
AU - Iwasaki, Yukiko
AU - Tahara, Koichiro
AU - Hayashi, Haeru
AU - Igarashi, Koji
AU - Fujio, Keishi
AU - Aoki, Junken
AU - Yatomi, Yutaka
N1 - Funding Information:
This work was supported by CREST from the JST/AMED and the Leading Advanced Projects for Medical Innovation (LEAP) from AMED to JA and YY, for the design of the study and collection, analysis, and interpretation of data.
Publisher Copyright:
© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Aim: To assess the utility of serum levels of phosphatidylserine-specific phospholipase A1 (PS-PLA1), a lipase involved in the production of lysophosphatidylserine with multi-immunomodulatory effects, in systemic lupus erythematosus (SLE). Method: Serum PS-PLA1 was measured in 161 patients with SLE (including 54 untreated patients), 80 disease controls (35 active rheumatoid arthritis [RA], 23 Sjögren's syndrome [SS], and 22 systemic sclerosis [SSc]), and 237 healthy controls. Results: Serum PS-PLA1 was significantly higher in SLE patients than in healthy controls, RA and SS patients. Although PS-PLA1 was significantly elevated in SSc and SS patients compared with healthy controls, PS-PLA1 was significantly higher in untreated SLE patients than in treated SLE patients and disease control patients. Receiver operating characteristic analysis revealed that a cut-off value of 18.2 ng/mL distinguished untreated SLE from disease control, with sensitivity and specificity of 71.4% and 57.5%, respectively. PS-PLA1 was significantly correlated with SLE Disease Activity Index (SLEDAI) and immunoglobulin G (IgG), and inversely correlated with white blood cell counts, lymphocyte counts, total complement hemolytic activity (CH50), complements C3, and C4 in SLE patients overall. Stepwise multiple regression identified SLEDAI, CH50, and IgG as significant parameters. In SLEDAI-based disease activity groups, PS-PLA1 was significantly higher in SLE patients with high disease activity than in those with low disease activity. PS-PLA1 decreased significantly in parallel with SLEDAI in 35 SLE patients whose paired serum samples were available pre- and post-treatment. Conclusion: Serum PS-PLA1 is associated with disease activity of SLE, indicating its possible use as a biomarker for monitoring SLE disease activity.
AB - Aim: To assess the utility of serum levels of phosphatidylserine-specific phospholipase A1 (PS-PLA1), a lipase involved in the production of lysophosphatidylserine with multi-immunomodulatory effects, in systemic lupus erythematosus (SLE). Method: Serum PS-PLA1 was measured in 161 patients with SLE (including 54 untreated patients), 80 disease controls (35 active rheumatoid arthritis [RA], 23 Sjögren's syndrome [SS], and 22 systemic sclerosis [SSc]), and 237 healthy controls. Results: Serum PS-PLA1 was significantly higher in SLE patients than in healthy controls, RA and SS patients. Although PS-PLA1 was significantly elevated in SSc and SS patients compared with healthy controls, PS-PLA1 was significantly higher in untreated SLE patients than in treated SLE patients and disease control patients. Receiver operating characteristic analysis revealed that a cut-off value of 18.2 ng/mL distinguished untreated SLE from disease control, with sensitivity and specificity of 71.4% and 57.5%, respectively. PS-PLA1 was significantly correlated with SLE Disease Activity Index (SLEDAI) and immunoglobulin G (IgG), and inversely correlated with white blood cell counts, lymphocyte counts, total complement hemolytic activity (CH50), complements C3, and C4 in SLE patients overall. Stepwise multiple regression identified SLEDAI, CH50, and IgG as significant parameters. In SLEDAI-based disease activity groups, PS-PLA1 was significantly higher in SLE patients with high disease activity than in those with low disease activity. PS-PLA1 decreased significantly in parallel with SLEDAI in 35 SLE patients whose paired serum samples were available pre- and post-treatment. Conclusion: Serum PS-PLA1 is associated with disease activity of SLE, indicating its possible use as a biomarker for monitoring SLE disease activity.
KW - biomarker
KW - disease activity
KW - lysophosphatidylserine
KW - phosphatidylserine-specific phospholipase A
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85071390239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071390239&partnerID=8YFLogxK
U2 - 10.1111/1756-185X.13689
DO - 10.1111/1756-185X.13689
M3 - Article
C2 - 31468739
AN - SCOPUS:85071390239
VL - 22
SP - 2059
EP - 2066
JO - APLAR Journal of Rheumatology
JF - APLAR Journal of Rheumatology
SN - 1756-1841
IS - 11
ER -